Valuation: Sensorion

Market Cap 76.18M 86.82M 71.95M 65.57M 123M 8.32B 124M 861M 333M 4.25B 326M 319M 13.66B P/E 2026 *
-2.09x
P/E 2027 * -3.2x
Enterprise Value 2.18M 2.49M 2.06M 1.88M 3.52M 239M 3.54M 24.69M 9.56M 122M 9.35M 9.14M 392M EV / Sales 2026 *
0.57x
EV / Sales 2027 * 0.08x
Free-Float
65.24%
Yield 2026 *
-
Yield 2027 * -
1 day-4.93%
1 week-21.59%
Current month-38.49%
1 month-40.04%
3 months-25.83%
6 months-56.76%
Current year-50.79%
1 week 6.88
Extreme 6.88
9.15
1 month 0.22
Extreme 0.2154
11.7
Current year 0.22
Extreme 0.2154
32.5
1 year 0.22
Extreme 0.2154
32.5
3 years 0.22
Extreme 0.2154
48.9
5 years 0.22
Extreme 0.2154
109.75
10 years 0.22
Extreme 0.2154
144.5
Manager TitleAgeSince
Chief Executive Officer 59 01/06/2026
Director of Finance/CFO - 26/06/2024
Chief Tech/Sci/R&D Officer - 11/12/2023
Director TitleAgeSince
Director/Board Member - 09/03/2015
Director/Board Member 43 -
Chairman 61 30/03/2023
Change 5-day change 1-year change 3-year change Capi.($)
-4.93%-21.59% - - 86.82M
-0.14%+4.33%+9.00%+31.64% 47.97B
-1.69%+1.48%+50.57%+34.53% 44.5B
+2.56%+7.34%+366.69%+608.26% 43.93B
+0.24%+2.85%+10.67%+94.47% 41.03B
-0.62%-1.11%+4.65%+48.91% 29.85B
-0.28%+1.07%+24.58%+155.58% 17.27B
-0.46%+1.20%+26.90%+42.21% 15.3B
-2.21%-4.70% - - 14.82B
+3.37%+9.21%+8.32% - 15.34B
Average -0.42%+2.35%+62.67%+145.08% 30B
Weighted average by Cap. +0.11%+2.86%+79.67%+160.28%

Financials

2026 *2027 *
Net sales 3.83M 4.36M 3.61M 3.29M 6.17M 418M 6.21M 43.26M 16.75M 214M 16.38M 16.02M 686M 15M 17.09M 14.16M 12.91M 24.16M 1.64B 24.34M 170M 65.65M 837M 64.17M 62.78M 2.69B
Net income -36M -41.03M -34M -30.99M -58M -3.93B -58.42M -407M -158M -2.01B -154M -151M -6.46B -28.79M -32.81M -27.19M -24.78M -46.38M -3.14B -46.71M -325M -126M -1.61B -123M -121M -5.16B
Net Debt -74M -84.33M -69.89M -63.69M -119M -8.08B -120M -836M -324M -4.13B -317M -310M -13.27B -75M -85.47M -70.83M -64.55M -121M -8.19B -122M -848M -328M -4.19B -321M -314M -13.45B
Logo Sensorion
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
66
Date Price Change
25/09/26 €7.135 -4.93%
24/09/26 €7.505 +1.97%
23/09/26 €7.360 -8.34%
22/09/26 €8.030 -10.68%
21/09/26 €8.990 -1.21%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.393EUR
Average target price
40.20EUR
Spread / Average Target
+443.76%

Quarterly revenue - Rate of surprise